Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998043 · ClinicalTrials.gov registry record · Phase 2
Study With Phage for CF Subjects With Pseudomonas Lung Infection
A Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection, sponsored by BiomX.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 14
- Study locations
NCT06998043 is a Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection that is actively recruiting participants, run by BiomX. The registered enrollment target is 63 participants, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (54% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT06998043, a Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection, is actively recruiting participants, sponsored by BiomX.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL BX004
Study Locations (14)
Florida
- Joe DiMaggio Children's Health - Hollywood
- Central Florida Pulmonary Group - Orlando
- Avanza Medical Center - Pensacola
California
- Stanford University - Palo Alto
- University of California San Francisco - San Francisco
New York
- New York Medical College - Hawthorne
- Northwell Health - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- National Jewish Health - Denver
New Jersey
- Rutgers, Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06998043
The ClinicalTrials.gov registry entry for NCT06998043 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (54% lower). The listed sponsor is BiomX, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06998043 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06998043 about?
NCT06998043 is a clinical study titled "Study With Phage for CF Subjects With Pseudomonas Lung Infection". The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background ...
What is the current status of trial NCT06998043?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2025-07-02. Estimated completion is 2026-09.
What conditions does trial NCT06998043 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF), Chronic Pseudomonas Aeruginosa Infection.
What interventions are being tested in trial NCT06998043?
The interventions under investigation include: Placebo (OTHER), BX004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06998043?
This trial is sponsored by BiomX, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06998043 being conducted?
This trial has 14 study locations across Alabama, Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
COMPLETED · Phase 2
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.